|
|
Volumn 23, Issue 22, 2005, Pages 4840-4841
|
|
Molecular targeting with cancer vaccines
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CANCER VACCINE;
CELL PROTEIN;
DENDRITIC CELL VACCINE;
GAMMA INTERFERON;
GEFITINIB;
INTERLEUKIN 5;
K RAS PROTEIN;
MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;
PROTEIN P53;
TUMOR ANTIGEN;
ADVANCED CANCER;
ANTIGEN PRESENTING CELL;
ANTIGEN SPECIFICITY;
CANCER IMMUNIZATION;
CANCER PREVENTION;
CANCER RELAPSE;
CD8+ T LYMPHOCYTE;
CELL PROLIFERATION;
CELLULAR IMMUNITY;
CLINICAL TRIAL;
CYTOTOXIC T LYMPHOCYTE;
DENDRITIC CELL;
DRUG ACTIVITY;
DRUG EFFECT;
DRUG EFFICACY;
DRUG TARGETING;
EDITORIAL;
FOLLOW UP;
GENE MUTATION;
GENE TARGETING;
HIGH RISK POPULATION;
HISTOCOMPATIBILITY COMPLEX;
HUMAN;
IMMUNE RESPONSE;
IMMUNOGENICITY;
INFECTION;
LUNG CANCER;
MICROMETASTASIS;
ONCOGENE K RAS;
OUTCOME ASSESSMENT;
PANCREAS CANCER;
PRIORITY JOURNAL;
PROTEIN EXPRESSION;
PROTEIN SECRETION;
PROTEIN TARGETING;
TUMOR GROWTH;
GENETICS;
NEOPLASM;
NOTE;
ONCOGENE RAS;
TUMOR SUPPRESSOR GENE;
ANTIGENS, NEOPLASM;
CANCER VACCINES;
CLINICAL TRIALS;
GENES, P53;
GENES, RAS;
HUMANS;
NEOPLASMS;
|
|
EID: 24644494306
PISSN: 0732183X
EISSN: None
Source Type: Journal
DOI: 10.1200/JCO.2005.03.910 Document Type: Editorial |
|
Times cited : (3)
|
|
References (6)
|
